 |
|
|
| |
On-treatment virologic response and tolerability of simeprevir, daclatasvir and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation (OLT): interim data from the Phase II SATURN study
|
| |
| |
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Forns X,1 Berenguer M,2 Herzer K,3 Sterneck M,4 Donato MF,5 Andreone P,6 Fagiuoli S,7 Cieciura T,8 Durlik M,9 Calleja JL,10 Mariņo Z,1 Simion A,11 Shukla U,12 Verbinnen T,11 Lenz O,11 Ouwerkerk-Mahadevan S,13 Peeters M,11 Kalmeijer R,12 Witek J12
1Liver Unit, Hospital Clinic, IDIBAPS and CIBEREHD, Barcelona, Spain; 2Department of Digestive Diseases, Hepatology and Liver Transplantation Unit, La Fe University Hospital and CIBEREHD, Valencia, Spain; 3Department for Gastroenterology and Hepatology, University Hospital Essen, Essen, Germany; 4Department of Hepatobiliary and Transplant Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 5Division of Digestive Diseases, IRCCS Maggiore Hospital, Milan, Italy; 6Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; 7Gastroenterology and Transplant Hepatology, Papa Giovanni XXIII Hospital, Bergamo, Italy; 8Department of Immunology, Transplant Medicine and Internal Diseases, Transplantation Institute, Medical University of Warsaw, Warsaw, Poland; 9Department of Transplantation Medicine and Nephrology, Transplantation Institute, Medical University of Warsaw, Warsaw, Poland; 10Department of Gastroenterology and Hepatology, University Hospital Puerta de Hierro Mahadahonda, Madrid, Spain; 11Janssen Infectious Diseases BVBA, Beerse, Belgium; 12Janssen Research & Development, LLC, Titusville, NJ, USA; 13Janssen Research and Development, Beerse, Belgium
|
| |
|
|
|
|
|
